Julia K. Rotow, MD

Articles by Julia K. Rotow, MD

Biomarker Testing and Advancements in EGFR-Mutant NSCLC Treatment Strategies

ByHatim Husain, MD,Wade Iams, MD,Julia K. Rotow, MD

November 13th 2023

Insights into diagnosing EGFR-mutant lung cancer and explores evolving first-line treatment strategies, incorporating recent developments, combinations, and clinical trial data, while addressing challenges in testing and patient management.

Trending on CancerNetwork

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Zenocutuzumab Earns FDA National Priority Voucher in Cholangiocarcinoma

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)